Atreca, a biopharmaceutical company in the clinical stage of development, focuses on the discovery and creation of antibody-based immunotherapeutics to treat numerous kinds of solid tumor types. The company's chief product candidate, ATRC-101, is a monoclonal antibody that utilizes an innovative mechanism of action and a target derived from an antibody identified through Atreca's proprietary discovery platform. ATRC-101 has in vitro reactions with the majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. Atreca is also developing two additional products, including APN-122597, which is a receptor tyrosine kinase targeting tumor tissues, and ATRC-501/MAM01, targeting the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Atreca has established its name in the industry through collaboration and license agreements. The company has a particular collaboration and license agreement with Xencor to conduct research, development, and commercialization on CD3 bispecific antibodies in oncology. The company also secured a licensing agreement with the Bill & Melinda Gates Medical Research Institute to work on the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Founded in 2010 and headquartered in San Carlos, California, Atreca is a prominent biopharmaceutical player, attracting industry-wide attention for its innovative research in clinical-stage treatments for solid tumor types.
Atreca, Inc.'s ticker is BCEL
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 51-200 employees working at Atreca, Inc.
It is https://www.atreca.com/
Atreca, Inc. is in the Healthcare sector
Atreca, Inc. is in the Biotechnology industry
The following five companies are Atreca, Inc.'s industry peers: